Neuphoria Therapeutics (NEUP) Shares Outstanding (Weighted Average) (2020 - 2026)

Neuphoria Therapeutics (NEUP) has 7 years of Shares Outstanding (Weighted Average) data on file, last reported at $5.4 million in Q1 2026.

• Quarterly Shares Outstanding (Weighted Average) rose 253.66% year-over-year to $5.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.4 million (up 253.66% YoY) and the FY2025 annual result came in at $1.6 million, up 95.01% from the prior year.
• Shares Outstanding (Weighted Average) rose to $5.4 million in Q1 2026 per NEUP's latest filing, from $3.4 million in the prior quarter.
• Across five years, Shares Outstanding (Weighted Average) topped out at $1.5 billion in Q3 2023 and bottomed at $43938.7 in Q2 2023.
• The 5-year median for Shares Outstanding (Weighted Average) is $1.6 million (2024), against an average of $191.2 million.
• The widest annual swing landed in 2023, when Shares Outstanding (Weighted Average) slumped 100.0%; it then jumped 1794.06% in 2024.
• Tracing NEUP's Shares Outstanding (Weighted Average) over 5 years: stood at $969.4 million in 2022, then tumbled by 99.92% to $773976.0 in 2023, then soared by 103.53% to $1.6 million in 2024, then soared by 115.28% to $3.4 million in 2025, then surged by 59.57% to $5.4 million in 2026.
• Per Business Quant, the three latest NEUP Shares Outstanding (Weighted Average) figures stand at $5.4 million (Q1 2026), $3.4 million (Q4 2025), and $2.2 million (Q3 2025).

Peer Comparison